Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer
Last Updated: Friday, October 22, 2021
The identification of predictive biomarkers is one of the greatest challenges of NSCLC research that should be optimized with solid methodological trial designs to maximize clinical outcomes. This review discusses the benefits and challenges of incorporating precision medicine into early- through late-phase metastatic NSCLC clinical trials.
Advertisement
News & Literature Highlights